Virpax® Successfully Completes Preclinical Dermal Safety Studies for Epoladerm(TM)

Stock Information for Virpax Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Virpax Pharmaceuticals Inc.

Virpax Pharmaceuticals Reports 2023 Year-End Results
Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price
Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.
Virpax Pharmaceuticals Announces Preliminary Results of ProbudurTM Pilot Study with the U.S. Army Institute of Surgical Research
Virpax Pharmaceuticals Announces Results of Special Shareholders Meeting
Virpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q Filing
 Virpax Pharmaceuticals Announces Leadership Transition
Virpax Pharmaceuticals Reports 2023 Third Quarter Results and Recent Developments

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.